Waking up repeatedly to urinate, or managing a child's bedwetting, can disrupt sleep and daily life for an entire household. Desmopressin is a long-established prescription option developed to address these exact concerns by helping the body retain water.
Key takeaways
- Desmopressin is approved as antidiuretic replacement therapy for central diabetes insipidus.
- It also treats temporary polyuria and polydipsia following head trauma or pituitary surgery.
- The drug is approved for managing primary nocturnal enuresis.
- It is not effective for nephrogenic diabetes insipidus.
- More than 150 registered clinical trials have studied desmopressin across its uses.
What Desmopressin Is
Desmopressin is marketed under the brand name Desmopressin Acetate and has a long history of clinical use. Chemically, it is a synthetic peptide compound (PubChem CID 5311065) with a molecular weight of approximately 1,069 g/mol. It works by replacing or supplementing the body's natural antidiuretic hormone activity, helping the kidneys conserve water.
What Desmopressin Is Approved For
Desmopressin acetate tablets are indicated as antidiuretic replacement therapy for central diabetes insipidus, a condition in which the body cannot properly retain water. They are also approved to manage temporary excessive urination and thirst that can follow head trauma or surgery near the pituitary gland. Diagnosis for these uses typically relies on tests such as water deprivation testing or response to antidiuretic hormone, and ongoing response can be tracked through urine volume and osmolality. Separately, desmopressin acetate tablets are approved for managing primary nocturnal enuresis. Notably, the medication is not effective for nephrogenic diabetes insipidus, a distinct form of the condition. No boxed warning is listed on the label for this product.
What The Evidence Shows
Desmopressin has been studied in 157 registered clinical trials covering its various approved and investigational uses. A completed Phase 4 trial evaluated a new checklist method for assessing nocturnal enuresis. A Phase 3 trial currently recruiting participants is examining systematic use of desmopressin (DDAVP) to prevent sodium overcorrection in patients with severe hyponatremia.
Reported Side Effects
Reports submitted to FAERS most frequently mention hyponatraemia, with 358 reports, reflecting the drug's known effect on water and sodium balance. Headache (274 reports), nausea (207), fatigue (174), vomiting (156), and dizziness (141) were also commonly reported. A notable number of reports cited drug ineffectiveness (263) or off label use (153). These figures represent counts of submitted reports, not confirmed incidence rates or evidence of causation.